Product
Lonafarnib
Aliases
LNF
3 clinical trials
3 indications
Indication
Hepatitis DIndication
ProgeriaIndication
ChronicClinical trial
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)Status: Completed, Estimated PCD: 2022-10-06
Clinical trial
An Open Label Phase II Trial of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome(HGPS) and Progeroid LaminopathiesStatus: Active (not recruiting), Estimated PCD: 2022-02-01
Clinical trial
Once Daily (QD) Dosing of Lonafarnib (LNF) Co-administered With Ritonavir (RTV) for Treatment of Chronic Hepatitis D Virus InfectionStatus: Active (not recruiting), Estimated PCD: 2024-12-31